Digestive Care Specialists Now Offering Endoscopic Sleeve Gastroplasty (ESG) With Insurance Coverage in Germantown, Maryland.
ESG is an outpatient procedure that helps patients lose 18-20% of their weight without incisions or surgery.
Share
ESG is an advanced, non-surgical weight loss procedure that uses an endoscopic suturing device to reduce stomach volume, helping patients achieve 18-20% total body weight loss without incisions or removal of stomach tissue. The procedure is performed entirely through the mouth, resulting in faster recovery times, minimal downtime, and fewer risks compared to traditional bariatric surgeries.
'We are thrilled to provide this life-changing procedure to our patients struggling with obesity,' said Dr. Halim Charbel, MD, Gastroenterologist and Endoscopic Weight Loss Specialist at Digestive Care Specialists. 'ESG bridges the gap between medical weight loss and surgical options, giving patients an effective, minimally invasive tool to achieve their health goals.'
Insurance Coverage Now Available
Medicare now covers ESG for patients meeting bariatric surgery criteria (BMI ≥40, or BMI ≥35 with an obesity-related condition such as diabetes, hypertension, or sleep apnea).
Commercial insurance carriers may cover ESG on a case-by-case basis, depending on plan requirements, prior authorizations, and appeals submitted by the medical practice.
'We are excited that Medicare coverage is now in place for ESG, and we are working closely with commercial insurers to obtain approval for eligible patients,' Dr. Charbel added. 'Our team supports patients through every step – from insurance authorization to nutritional counseling and long-term follow-up.'
About Digestive Care Specialists
Digestive Care Specialists is a leading gastroenterology practice in Maryland, specializing in advanced endoscopic weight loss procedures, general gastroenterology, and digestive health optimization. The team is committed to providing compassionate, evidence-based care to help patients achieve better health and quality of life.
The ESG procedure is performed at Holy Cross Germantown Hospital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
21 minutes ago
- Fast Company
UnitedHealth Group confirms DOJ investigation over Medicare billing
BY UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said Thursday that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth said in the filing Thursday that it 'has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.' UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Its share price topped $630 last fall to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. The stock price slipped another 3%, or $10.35, to $282.16 in midday trading Thursday. That represents a 55% drop from its all-time high. The Dow Jones Industrial Average, of which UnitedHealth is a component, also fell slightly. Meanwhile, the broader S&P 500 rose. UnitedHealth will report its second-quarter results next Tuesday. —Tom Murphy, AP health writer
Yahoo
42 minutes ago
- Yahoo
Why Are West Pharmaceutical Services (WST) Shares Soaring Today
What Happened? Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook. The medical instruments supplier announced net sales of $766.5 million, a 9.2% increase from the prior year, which surpassed analyst expectations. The company's reported earnings per share (EPS) of $1.82 represented a significant beat over the consensus estimate of $1.51. In light of the strong performance, management increased its full-year 2025 financial outlook. West Pharmaceutical Services raised its net sales guidance to a range of $3.040 billion to $3.060 billion and lifted its adjusted-diluted EPS forecast to between $6.65 and $6.85. Additionally, the company's Board of Directors approved a fourth-quarter dividend of $0.22 per share. Is now the time to buy West Pharmaceutical Services? Access our full analysis report here, it's free. What Is The Market Telling Us West Pharmaceutical Services's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for West Pharmaceutical Services and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 6 days ago when the stock dropped 6.3% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. West Pharmaceutical Services is down 15.9% since the beginning of the year, and at $276.29 per share, it is trading 20.6% below its 52-week high of $347.87 from January 2025. Investors who bought $1,000 worth of West Pharmaceutical Services's shares 5 years ago would now be looking at an investment worth $1,052. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
New York Post
an hour ago
- New York Post
UnitedHeath shares fall after health-care giant admits DOJ fraud probe into Medicare business
Shares of UnitedHealth Group slipped Thursday after the health-care giant said it was under a Department of Justice investigation. The company said it has started complying with both criminal and civil requests from federal investigators and it was cooperating with them. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. 3 UnitedHealth's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. wolterke – Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper then said earlier this month that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth Group said that it reached out to the Justice Department 'after reviewing media reports about investigations into certain aspects of the company's participation in the Medicare program.' 3 Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. AP UnitedHealth runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Last year, its share price topped $630 to reach a new all-time high. But company shares have mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A 26-year-old suspect, Luigi Mangione, has been charged in connection with the shooting. 3 A 26-year-old suspect, Luigi Mangione, has been charged in connection with last year's shooting of the head of the healthcare group. AP In April, shares plunged after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned and the company withdrew its forecast. The stock price slipped another 2%, or $5.12, to $287.39 Thursday morning. That represents a 54% drop from its all-time high. UnitedHealth will report its second-quarter results next Tuesday.
